[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644715":3},{"organization":4,"armGroups":7,"interventions":37,"overallOfficials":43,"centralContacts":54,"locations":60,"responsibleParty":76,"collaborators":43,"id":78,"slug":43,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":43,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":43,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":43,"overallStatus":63,"whyStopped":43,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"argenx","INDUSTRY",[8,14,19,23,27,32],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1 - Adimanebart IV","EXPERIMENTAL","Participants randomized to receive adimanebart IV",[13],"Biological: Adimanebart IV",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 1 - Adimanebart SC (formulation A)","Participants randomized to receive adimanebart SC",[18],"Biological: Adimanebart SC - formulation A",{"label":20,"type":10,"description":21,"interventionNames":22},"Part 2 - Adimanebart SC (formulation A) in lower body weights","Participants with body weight \\\u003C 60 kg will receive adimanebart SC",[18],{"label":24,"type":10,"description":25,"interventionNames":26},"Part 2 - Adimanebart SC (formulation A) in higher body weights","Participants with body weight between 100 and 130 kg will receive adimanebart SC",[18],{"label":28,"type":10,"description":29,"interventionNames":30},"Part 3 - Adimanebart SC (formulation B)","Participants randomized to receive adimanebart SC formulation B",[31],"Biological: Adimanebart SC - formulation B",{"label":33,"type":10,"description":34,"interventionNames":35},"Part 3 - Adimanebart SC (formulation C)","Participants randomized to receive adimanebart SC formulation C",[36],"Biological: Adimanebart SC - formulation C",[38,44,48,51],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"BIOLOGICAL","Adimanebart IV","Intravenous infusion of adimanebart IV",[9],null,{"type":39,"name":45,"description":46,"armGroupLabels":47,"otherNames":43},"Adimanebart SC - formulation A","Subcutaneous administration of Adminanebart SC",[15,24,20],{"type":39,"name":49,"description":46,"armGroupLabels":50,"otherNames":43},"Adimanebart SC - formulation B",[28],{"type":39,"name":52,"description":46,"armGroupLabels":53,"otherNames":43},"Adimanebart SC - formulation C",[33],[55],{"name":56,"role":57,"phone":58,"phoneExt":43,"email":59},"Sabine Coppieters, MD","CONTACT","857-350-4834","clinicaltrials@argenx.com",[61],{"facility":62,"status":63,"city":64,"state":43,"zip":65,"country":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Altasciences","RECRUITING","Montreal","H3P 3P1","Canada",{"type":68,"coordinates":69},"Point",[70,71],-73.58781,45.50884,{"lat":71,"lon":70},[74],{"name":75,"role":57,"phone":58,"phoneExt":43,"email":59},"Gaetano Morelli, MD",{"type":77,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100644715",false,"NCT07673601","A Study to Assess the Absolute Bioavailability and How Adimanebart SC Moves Through the Body in Healthy Adult Participants","A Phase 1, Open-Label, Randomized, Single Dose, Parallel-Group Study to Assess the Absolute Bioavailability and Evaluate the Effect of Body Weight on the Pharmacokinetics of Adimanebart SC in Healthy Adult Participants","Inclusion Criteria:\n\n* Is at least the local legal age of consent and aged 18 to 65 years, inclusive, when signing the ICF.\n* Has a body weight between 60 and 100 kg and a BMI between 18.5 and 30 kg\u002Fm2, inclusive, at screening and on day -1 for part 1 and part 3, or has a body weight \\\u003C60 kg or between 100 and 130 kg and a BMI between 18.5 and 38.0 kg\u002Fm2, inclusive, at screening and on day -1 for part 2.\n* Discontinues and refrains from using all medications, including nonprescription and prescription medications, for ≥2 weeks before IMP administration, except for hormonal contraceptives and hormone replacement therapy in female participants. The occasional use of acetaminophen or ibuprofen is allowed.\n\nExclusion Criteria:\n\n* Has any current or past clinically meaningful medical or psychiatric condition, including severe hypersensitivity reactions to drugs and\u002For food that, in the investigator's opinion, would confound the study results or put the participant at undue risk.\n* Previously participated in an adimanebart clinical study and received at least 1 dose of IMP.\n* Is currently participating in another interventional clinical study, or has received an IMP in another clinical study within 12 weeks or 5 half-lives (whichever is longer) before screening.",true,"ALL","18 Years","65 Years",{"count":89,"type":90},52,"ESTIMATED","INTERVENTIONAL",[93],"PHASE1","This study aims to find out how much adimanebart gets into the blood circulation of healthy adults. Researchers will measure the amount of adimanebart in blood over time to learn how it moves through the body. The drug's safety will also be assessed.\n\nThe participants will be assigned to one of 3 parts of the study: part 1 investigates the absolute bioavailability; part 2 investigates the effect of different body weights on adimanebart in blood after subcutaneous (SC) dosing; part 3 investigates formulation adaptations.\n\nParticipants will be in the study for approximately up to 24 weeks.",[96,97],"Healthy Volunteers (HV)","Healthy Volunteer","2026-06-23",{"date":100,"type":101},"2026-06-29","ACTUAL",{"date":103,"type":101},"2026-06-12",{"date":105,"type":90},"2026-12",{"name":5,"class":6},1]